105 related articles for article (PubMed ID: 16416673)
21. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.
Ishizaki T; Chiba K; Manabe K; Koyama E; Hayashi M; Yasuda S; Horai Y; Tomono Y; Yamato C; Toyoki T
Clin Pharmacol Ther; 1995 Aug; 58(2):155-64. PubMed ID: 7648765
[TBL] [Abstract][Full Text] [Related]
22. Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.
Chang M; Tybring G; Dahl ML; Götharson E; Sagar M; Seensalu R; Bertilsson L
Br J Clin Pharmacol; 1995 May; 39(5):511-8. PubMed ID: 7669487
[TBL] [Abstract][Full Text] [Related]
23. Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole.
Fan L; Wang G; Wang LS; Chen Y; Zhang W; Huang YF; Huang RX; Hu DL; Wang D; Zhou HH
Acta Pharmacol Sin; 2007 Oct; 28(10):1685-92. PubMed ID: 17883958
[TBL] [Abstract][Full Text] [Related]
24. Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration.
Niioka T; Uno T; Sugimoto K; Sugawara K; Hayakari M; Tateishi T
Eur J Clin Pharmacol; 2007 Nov; 63(11):1031-8. PubMed ID: 17701405
[TBL] [Abstract][Full Text] [Related]
25. Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4.
Böttiger Y
Eur J Clin Pharmacol; 2006 Aug; 62(8):621-5. PubMed ID: 16791583
[TBL] [Abstract][Full Text] [Related]
26. Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes.
Roh HK; Kim PS; Lee DH; Tybring G; Sagar M; Park CS; Seensalu R; Bertilsson L
Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):112-9. PubMed ID: 15447734
[TBL] [Abstract][Full Text] [Related]
27. Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
Niioka T; Yasui-Furukori N; Uno T; Sugawara K; Kaneko S; Tateishi T
Ther Drug Monit; 2006 Jun; 28(3):321-5. PubMed ID: 16778714
[TBL] [Abstract][Full Text] [Related]
28. CYP2C19 polymorphism and proton pump inhibitors.
Klotz U; Schwab M; Treiber G
Basic Clin Pharmacol Toxicol; 2004 Jul; 95(1):2-8. PubMed ID: 15245569
[TBL] [Abstract][Full Text] [Related]
29. The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment.
de Bortoli N; Martinucci I; Giacchino M; Blandizzi C; Marchi S; Savarino V; Savarino E
Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1361-9. PubMed ID: 23802731
[TBL] [Abstract][Full Text] [Related]
30. Additional discussions regarding the altered metabolism and transport of omeprazole after long-term use of St John's wort.
Xie HG
Clin Pharmacol Ther; 2005 Oct; 78(4):440-1. PubMed ID: 16198664
[No Abstract] [Full Text] [Related]
31. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
[TBL] [Abstract][Full Text] [Related]
32. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Chirality; 2005 Jun; 17(6):338-44. PubMed ID: 15856433
[TBL] [Abstract][Full Text] [Related]
33. Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.
Lawson EB; Wu JC; Baldwin RM; Ingelman-Sundberg M; Rosenborg S; Yim DS; Yin OQ; Capparelli EV; Ma JD
Eur J Clin Pharmacol; 2012 Apr; 68(4):407-13. PubMed ID: 22009190
[TBL] [Abstract][Full Text] [Related]
34. CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole.
Jin SK; Kang TS; Eom SO; Kim JI; Lee HJ; Roh J
J Clin Pharm Ther; 2009 Aug; 34(4):437-46. PubMed ID: 19583677
[TBL] [Abstract][Full Text] [Related]
35. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
[TBL] [Abstract][Full Text] [Related]
36. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
[TBL] [Abstract][Full Text] [Related]
37. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
Clin Pharmacol Ther; 2006 Nov; 80(5):539-48. PubMed ID: 17112810
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.
Calabresi L; Pazzucconi F; Ferrara S; Di Paolo A; Tacca MD; Sirtori C
Pharmacol Res; 2004 May; 49(5):493-9. PubMed ID: 14998561
[TBL] [Abstract][Full Text] [Related]
39. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Furuta T; Sugimoto M; Shirai N; Ishizaki T
Pharmacogenomics; 2007 Sep; 8(9):1199-210. PubMed ID: 17924835
[TBL] [Abstract][Full Text] [Related]
40. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
Sohn DR; Kwon JT; Kim HK; Ishizaki T
Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
